GSK PLC (GLAXF)
22.65
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
GSK Enterprise Value: 108.86B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 31, 2024 | 108.86B |
May 30, 2024 | 108.86B |
May 29, 2024 | 108.25B |
May 28, 2024 | 108.25B |
May 24, 2024 | 110.13B |
May 23, 2024 | 110.13B |
May 22, 2024 | 109.27B |
May 21, 2024 | 106.68B |
May 20, 2024 | 107.23B |
May 17, 2024 | 108.41B |
May 16, 2024 | 107.23B |
May 15, 2024 | 109.47B |
May 14, 2024 | 109.35B |
May 13, 2024 | 108.86B |
May 10, 2024 | 108.25B |
May 09, 2024 | 105.50B |
May 08, 2024 | 105.50B |
May 07, 2024 | 106.35B |
May 06, 2024 | 102.71B |
May 03, 2024 | 102.71B |
May 02, 2024 | 102.13B |
May 01, 2024 | 102.13B |
April 30, 2024 | 101.32B |
April 29, 2024 | 103.36B |
April 26, 2024 | 97.45B |
Date | Value |
---|---|
April 25, 2024 | 97.45B |
April 24, 2024 | 97.45B |
April 23, 2024 | 96.18B |
April 22, 2024 | 99.30B |
April 19, 2024 | 98.87B |
April 18, 2024 | 98.87B |
April 17, 2024 | 98.87B |
April 16, 2024 | 98.87B |
April 15, 2024 | 98.87B |
April 12, 2024 | 98.34B |
April 11, 2024 | 100.11B |
April 10, 2024 | 101.48B |
April 09, 2024 | 101.48B |
April 08, 2024 | 101.11B |
April 05, 2024 | 101.11B |
April 04, 2024 | 101.73B |
April 03, 2024 | 102.46B |
April 02, 2024 | 101.75B |
April 01, 2024 | 98.46B |
March 31, 2024 | 103.81B |
March 28, 2024 | 101.84B |
March 27, 2024 | 100.98B |
March 26, 2024 | 100.98B |
March 25, 2024 | 104.25B |
March 22, 2024 | 98.69B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
74.54B
Minimum
Oct 18 2022
160.96B
Maximum
Dec 27 2019
121.25B
Average
131.92B
Median
Enterprise Value Benchmarks
Adaptimmune Therapeutics PLC | 142.58M |
Biodexa Pharmaceuticals Plc | 1.860M |
Verona Pharma PLC | 772.32M |
NuCana PLC | -8.064M |
Autolus Therapeutics PLC | 356.16M |
Enterprise Value Related Metrics
Net Income (Quarterly) | 1.327B |
Revenue (Quarterly) | 9.339B |
Total Expenses (Quarterly) | 7.449B |
EPS Diluted (Quarterly) | 0.3222 |
Gross Profit Margin (Quarterly) | 73.24% |
Profit Margin (Quarterly) | 14.21% |
Earnings Yield | 5.63% |
Operating Earnings Yield | 8.59% |
Normalized Earnings Yield | 6.218 |